Navigation Links
Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
Date:5/19/2008

Preclinical Results Show Neo-Bladder Replacement Structurally Similar to Native Bladder by Six Months; Data Presented at May 18 Press Briefing and

Poster Session

ORLANDO, Fla. and EAST NORRITON, Pa., May 19 /PRNewswire/ -- Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-vessels, presented preclinical efficacy data for its Tengion Neo-Bladder Replacement(TM) at the Annual Meeting of the American Urological Association (AUA) in Orlando, Florida on May 18, 2008. The data were presented by Tim Bertram, D.V.M., Ph.D., Senior Vice President, Science and Technology of Tengion, during both a poster session and a press briefing sponsored by the AUA.

"In this well-established preclinical model, the Neo-Bladder Replacement was able to achieve functional recovery and a regenerative response that emulated the native bladder," said Dr. Bertram. "These data join the existing body of information from the preclinical studies of our first product candidate, the Tengion Neo-Bladder Augment, and underscore the promise and potential of our Autologous Organ Regeneration Platform as a foundation for our pipeline of regenerative medicine products."

The preclinical study presented at AUA was a six-month, single-arm study to evaluate the application of Tengion's technology to regenerate an entire urinary bladder. Neo-Bladder Replacements were produced from autologous bladder cells seeded onto a biodegradable scaffold and were then surgically implanted into 23 large mammals.

In this study:

-- Tengion's Neo-Bladder Replacement was able to regenerate an entire

urinary bladder within six months after implantation

-- The regenerated bladder demonstrated near-baseline capacity and

cystography by six months after implantation

-- The regenerated bladder wall structure consisted of three layers:

urothelium, muscle, and serosa by
'/>"/>

SOURCE Tengion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... -- In part four of a blog series ... a strategic asset, Mary Baxter, MBA, RPh ., ... Innovation Delivery Solutions business, discusses how expanding patient access ... patients. "Every hospital pharmacist knows that filling ... in a value-based healthcare world," Baxter says. "For the ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company ... Tom Wegman , will present at the upcoming Jefferies & Company 2010 ... 2:30pm EDT . , ... A live webcast of the presentation can be accessed under "Calendar ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today ... Thursday, June 10, 2010 at The Grand Hyatt Hotel in ... Executive Officer, will discuss the Company,s business strategy and historical financial performance at ... , , ...
Cached Medicine Technology:BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference 2BioSpecifics Technologies Corp. to Present at Jefferies & Company 2010 Global Life Sciences Conference 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:9/1/2014)... 01, 2014 Ontraport , one ... that was developed to automate the small intricacies of ... of Shane Michaels, prompting an investigative review. , ... duty of managing all of the small details involved ... overwhelming,” reports Michaels. “That’s why Ontraport has become so ...
(Date:9/1/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on DePuy Synthes Craniomaxillofacial ... on August 28, that specific lots of DePuy Synthes ... as the device may reverse directions after surgery. ... Distraction System is an implant used to lengthen and/or ...
(Date:9/1/2014)... Nevada (PRWEB) September 01, 2014 Beginning ... to over 3,000 medical professionals and 10,000 consumers for ... is a 5-day gathering of the nation’s top medical ... associated diseases or conditions. The week-long event contains more ... evidence-based scientific instruction available in the pain management field. ...
(Date:8/31/2014)... 31, 2014 An analysis of 32 ... has revealed a link between lower levels of Vitamin ... in the August 2014 issue of American ... main form of Vitamin D found in blood. ... 25-Hydroxyvitamin D lower than 9 nanograms/milliliter (ng/mL) were twice ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 The FDA ... Nutrition Facts label. If adopted, the proposed changes would ... addition of “added sugars” on the label, and a ... to keep “added sugars” off the label. NutriGold fully ... consumers make healthier food choices. “After 20 years, it's ...
Breaking Medicine News(10 mins):Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4
... of a new use for magnetic levitation, or "maglev," ... trains to float above the tracks. In ACS, bi-weekly ... describe putting maglev to use in an inexpensive sensor ... Whitesides and colleagues note that measurements of a substance,s ...
... in Spanish . Ensuring the optimum ... in prostate cancer treatment manages to control the illness in ... research undertaken at the University Hospital of Navarre and published ... the American Society of Brachytherapy. As is known, brachytherapy ...
... (June 23, 2010) Children who experience maltreatment ... likely to experience frequent headaches, including chronic migraine, as ... Headache Society,s 52nd Annual Scientific Meeting in Los Angeles ... Experiences (ACE) Study of 17,337 adult members of the ...
... Some 19 percent of soldiers returning from Iraq have ... While prevalence of migraine among the U.S. military ... quality in soldiers with chronic headaches including post-traumatic headache ... Army Medical Center in Tacoma, WA presenting at American ...
... having the most expensive health care system, the United ... countriesAustralia, Canada, Germany, the Netherlands, New Zealand, and the ... areas: quality, efficiency, access to care, equity and the ... a new Commonwealth Fund report. While there is room ...
... research professor in the department of physics at NJIT, ... Research Council (NRC) of the National Academies ( www.nationalacademies.org ... vehicles in the aftermath of Toyota,s large recalls. The ... and July 1, 2010 in Washington, DC, includes notable ...
Cached Medicine News:Health News:Optimizing brachytherapy dose on the same day as the implant can control prostate cancer 2Health News:US ranks last among 7 countries on health system performance 2Health News:US ranks last among 7 countries on health system performance 3Health News:NJIT professor heads panel studying sudden car acceleration 2
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
... designed to have the following properties and ... sections, cell cultures, specimens with aqueous embedding ... cover glass thickness (0.14...0.18 mm) and temperatures ... correction collar can also be used for ...
Medicine Products: